Last reviewed · How we verify

Seriphos (DEXFOSFOSERINE)

Phase 2 active Small molecule

Seriphos (generic name: DEXFOSFOSERINE) is a dexfosfoserine drug. It is currently in Phase 2 development.

Seriphos works by binding to the metabotropic glutamate receptor 8, a protein involved in regulating neurotransmitter release.

Seriphos, also known as dexfosfoserine, is a small molecule modality targeting the metabotropic glutamate receptor 8. Its exact commercial status is unknown, and it has not received FDA approval for any indications. As a drug class, dexfosfoserine is still in the development phase, and its pharmacokinetic properties, such as half-life and bioavailability, are not publicly disclosed. Further research is needed to determine its efficacy and safety profile. The current owner of Seriphos is not specified.

Likelihood of approval
12.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • CNS / neurology attrition -3.0pp
    CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameDEXFOSFOSERINE
Drug classdexfosfoserine
TargetMetabotropic glutamate receptor 6, Metabotropic glutamate receptor 7, Metabotropic glutamate receptor 4
ModalitySmall molecule
Therapeutic areaNeuroscience
PhasePhase 2

Mechanism of action

Imagine your brain cells talking to each other through chemical messengers called neurotransmitters. Seriphos helps control how these messengers are released by binding to a specific receptor on the brain cells. This can affect how the brain cells communicate with each other.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Seriphos

What is Seriphos?

Seriphos (DEXFOSFOSERINE) is a dexfosfoserine drug.

How does Seriphos work?

Seriphos works by binding to the metabotropic glutamate receptor 8, a protein involved in regulating neurotransmitter release.

What is the generic name of Seriphos?

DEXFOSFOSERINE is the generic (nonproprietary) name of Seriphos.

What drug class is Seriphos in?

Seriphos belongs to the dexfosfoserine class. See all dexfosfoserine drugs at /class/dexfosfoserine.

What development phase is Seriphos in?

Seriphos is in Phase 2.

What does Seriphos target?

Seriphos targets Metabotropic glutamate receptor 6, Metabotropic glutamate receptor 7, Metabotropic glutamate receptor 4 and is a dexfosfoserine.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing